--- title: "Senti Biosciences Holdings (SNTI) news: offering" url: "https://aibio.space/companies/senti-biosciences/" publisher: "aibio.space (Biotech Investor Relations News)" summary: "SNTI offering, convertible notes, Nasdaq notice and merger news: Senti Biosciences files $300,000,000 shelf and sets up $17,500,000 at-the-market program." --- SNTI Senti Biosciences Holdings, Inc. NASDAQ · United States # Senti Biosciences Holdings (SNTI) news SNTI offering, convertible notes and Nasdaq notice news Mergers · 2026-10-13 ## [Senti Biosciences adjourns annual meeting to seek more votes for merger proposal](https://aibio.space/news/senti-biosciences-adjourns-annual-meeting-seek-more-votes-merger/) Senti adjourned its October 8, 2026 annual meeting without conducting any business to seek more votes for a merger proposal. The company reported $6.5 million of cash and cash equivalents at June 30, 2026, after using $43.4 million in operations in 2025. ## Latest Senti Biosciences Holdings news 1. 2026-09-03 Debt Financing [Senti Biosciences unit sells $2.0 million in convertible notes to NSG](https://aibio.space/news/senti-biosciences-unit-sells-2-0-million-convertible-notes-nsg/) The notes were issued under an April 27, 2026 purchase agreement, as amended on September 1, 2026. A separate $2.5 million equity commitment was signed the same day. 2. 2026-08-27 Listings [Senti Biosciences gets two Nasdaq notices, on bid price and a $3.4M equity deficit](https://aibio.space/news/senti-biosciences-gets-two-nasdaq-notices-bid-price-3-4m-equity/) Nasdaq flagged Senti's sub-$1 share price and a stockholders' deficit below the $2.5 million minimum. The bid-price clock runs to Feb. 23, 2027; the equity plan is due Oct. 11. 3. 2026-08-14 Debt Financing [Senti Biosciences unit sells $4.0 million of convertible notes to Celadon](https://aibio.space/news/senti-biosciences-unit-sells-4-0-million-convertible-notes-celadon/) The notes were issued under an April 27, 2026 purchase agreement. The filing also ties the company to a potential merger with a contingent value right that could pay up to $60.0 million in cash. 4. 2026-07-15 Mergers [Senti Biosciences signs merger agreement with Celadon affiliate, with CVRs tied to SENTI-202](https://aibio.space/news/senti-biosciences-signs-merger-agreement-celadon-affiliate-cvrs-tied/) Senti Biosciences agreed on July 14, 2026 to move most of its business, including lead candidate SENTI-202, to an affiliate of its largest stockholder. Holders would receive contingent value rights worth up to $60 million that pay only if milestones are met, while the company used $43.4 million in operations in 2025. 5. 2026-05-20 Debt Financing [Senti Biosciences issues $10.0 million senior secured convertible notes](https://aibio.space/news/senti-biosciences-issues-10-0-million-senior-secured-convertible-notes/) Celadon Partners SPV 24 bought the notes, and Acquiom Agency Services LLC was named collateral agent. 6. 2026-05-14 Debt Financing [Senti Biosciences signs up to $40 million in convertible note financing](https://aibio.space/news/senti-biosciences-signs-up-40-million-convertible-note-financing/) An affiliate of Celadon Partners SPV 24 may buy notes in two tranches. The first tranche is $10 million and is expected to close in May. 7. 2026-05-01 Mergers [Senti Biosciences agrees to sell $10.0 million of secured convertible notes to Celadon affiliate](https://aibio.space/news/senti-biosciences-agrees-sell-10-0-million-secured-convertible-notes/) Senti Biosciences agreed to sell up to $40.0 million of secured convertible notes to an affiliate of its largest stockholder. If the notes are not converted, the company must pay 200% of principal in cash at maturity, and the second tranche depends on a related deal that could pay up to $60.0 million. 8. 2025-03-24 Financings [Senti Biosciences files $300,000,000 shelf and sets up $17,500,000 at-the-market program](https://aibio.space/news/senti-biosciences-files-300-000-000-shelf-sets-up-17-500-000-market/) Leerink Partners will act as sales agent for a 3.0% commission. The company's public float was approximately $57.81 million. ## Senti Biosciences Holdings at a glance - **Ticker**: SNTI - **Listing**: NASDAQ - **Country**: United States - **Cash, Jun 30, 2026**: $6.5 million ### Related companies - [Tyra Biosciences](https://aibio.space/companies/tyra-biosciences/) NASDAQ: TYRA - [Amarantus Bioscience Holdings](https://aibio.space/companies/amarantus-bioscience/) OTC: AMBS - [BioStem Technologies](https://aibio.space/companies/biostem-technologies/) NASDAQ: BSEM - [Precigen](https://aibio.space/companies/precigen/) NASDAQ: PGEN - [Evofem Biosciences](https://aibio.space/companies/evofem-biosciences/) OTC: EVFM - [Aspira Women's Health](https://aibio.space/companies/aspira-women-s-health/) OTC: AWHL - [GridAI Technologies](https://aibio.space/companies/gridai-technologies/) NASDAQ: GRDX - [Nurix Therapeutics](https://aibio.space/companies/nurix-therapeutics/) NASDAQ: NRIX ### Also on NASDAQ - [BGM Group](https://aibio.space/companies/bgm/) BGM - [ClearPoint Neuro](https://aibio.space/companies/clearpoint-neuro/) CLPT - [Cingulate](https://aibio.space/companies/cingulate/) CING - [Alpha Tau Medical](https://aibio.space/companies/alpha-tau-medical/) DRTS - [Outlook Therapeutics](https://aibio.space/companies/outlook-therapeutics/) OTLK - [bioAffinity Technologies](https://aibio.space/companies/bioaffinity-technologies/) BIAF ## Senti Biosciences Holdings annual financials | Line | FY2025 | FY2024 | |---|---|---| | Revenue | | [$0](https://www.sec.gov/Archives/edgar/data/1854270/000185427025000042/) | | Research and development | [$37.6 million](https://www.sec.gov/Archives/edgar/data/1854270/000162828026021580/) | [$34.4 million](https://www.sec.gov/Archives/edgar/data/1854270/000162828026021580/) | | Net income (loss) | [-$61.4 million](https://www.sec.gov/Archives/edgar/data/1854270/000162828026021580/) | [-$52.8 million](https://www.sec.gov/Archives/edgar/data/1854270/000162828026021580/) | | Cash from operations | [-$43.4 million](https://www.sec.gov/Archives/edgar/data/1854270/000162828026021580/) | [-$41.4 million](https://www.sec.gov/Archives/edgar/data/1854270/000162828026021580/) | | Cash and equivalents | [$16.4 million](https://www.sec.gov/Archives/edgar/data/1854270/000162828026057110/) | [$48.3 million](https://www.sec.gov/Archives/edgar/data/1854270/000162828026021580/) | Latest balance sheet, Jun 30, 2026 (10-Q): cash and equivalents $6.5 million. Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice. ## Questions about Senti Biosciences Holdings Has Senti Biosciences Holdings raised money recently? Our latest story on this, dated Mar 24, 2025: "Senti Biosciences files $300,000,000 shelf and sets up $17,500,000 at-the-market program". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/senti-biosciences-files-300-000-000-shelf-sets-up-17-500-000-market/). Has Senti Biosciences Holdings sold convertible notes? Our latest story on this, dated Sep 3, 2026: "Senti Biosciences unit sells $2.0 million in convertible notes to NSG". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/senti-biosciences-unit-sells-2-0-million-convertible-notes-nsg/). Has Senti Biosciences Holdings received a Nasdaq deficiency notice? Our latest story on this, dated Aug 27, 2026: "Senti Biosciences gets two Nasdaq notices, on bid price and a $3.4M equity deficit". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/senti-biosciences-gets-two-nasdaq-notices-bid-price-3-4m-equity/). Is Senti Biosciences Holdings involved in a merger or acquisition? Our latest story on this, dated Oct 13, 2026: "Senti Biosciences adjourns annual meeting to seek more votes for merger proposal". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/senti-biosciences-adjourns-annual-meeting-seek-more-votes-merger/). What is the ticker symbol of Senti Biosciences Holdings? Senti Biosciences Holdings, Inc. trades under the ticker SNTI on NASDAQ. Where is Senti Biosciences Holdings listed? Senti Biosciences Holdings, Inc. is listed on NASDAQ. What is the SEC CIK of Senti Biosciences Holdings? The SEC Central Index Key (CIK) for Senti Biosciences Holdings, Inc. is 1854270. Its filings are on SEC EDGAR. How many shares does Senti Biosciences Holdings have outstanding? 31,144,754 shares as of 2026-07-31, per the cover page of its 10-Q filed 2026-08-14. Which country or territory is Senti Biosciences Holdings listed under? Our directory records Senti Biosciences Holdings, Inc. under United States. What does Senti Biosciences Holdings do? Our directory classifies Senti Biosciences Holdings, Inc. as: Biotechnology. This is a directory classification, not a description of the pipeline. What is the ISIN of Senti Biosciences Holdings? The ISIN recorded for Senti Biosciences Holdings, Inc. is US8169441024. Does aibio.space cover Senti Biosciences Holdings? aibio.space lists Senti Biosciences Holdings, Inc. among 2,820 public biotech companies and publishes its news here as stories appear. Where is Senti Biosciences Holdings incorporated? SEC records list its state or country of incorporation as DE. Is Senti Biosciences Holdings profitable? Senti Biosciences Holdings, Inc. reported a net loss of $61.4 million for the fiscal year ended Dec 31, 2025, and used $43.4 million of cash in operations, per its annual report to the SEC. How much does Senti Biosciences Holdings spend on research and development? $37.6 million in the fiscal year ended Dec 31, 2025, per its annual report. ## Investor discussion: Senti Biosciences Holdings Members talk about Senti Biosciences Holdings (SNTI). Reader posts, not aibio.space reporting, and not investment advice. Rules 1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information. 2. **Say whether you hold the stock.** Every post states long, short or no position. 3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you. 4. **No buy or sell calls and no price targets.** 5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them. 6. **No personal details and no spam.** No links at all for your first 7 days as a member. Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion). ## Capital-markets timeline Financings, listing notices, splits, legal actions and other investor events at Senti Biosciences Holdings, newest first. Each line links the filing it comes from. 1. 2026-10-15 Listings Reported a shareholder vote on a reverse stock split or more authorized shares. SEC Form 8-K (Items 5.07). [Source](https://www.sec.gov/Archives/edgar/data/1854270/000162828026065992/snti-20261015.htm) 2. 2026-10-13 Mergers Reported a merger or acquisition agreement. SEC Form 8-K (Items 8.01). [Source](https://www.sec.gov/Archives/edgar/data/1854270/000162828026065685/snti-20261008.htm) 3. 2026-09-04 Financings Reported a financing. SEC Form 8-K (Items 1.01,2.03,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1854270/000162828026060600/snti-20260903.htm) 4. 2026-09-02 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 1.01,3.01). [Source](https://www.sec.gov/Archives/edgar/data/1854270/000162828026060124/snti-20260827.htm) 5. 2026-07-15 Mergers Reported a merger or acquisition agreement. SEC Form 8-K (Items 1.01,2.02,5.01,7.01,8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1854270/000162828026048248/exhibit991-pressrelease.htm) 6. 2026-05-08 Listings Filed to end its SEC reporting. SEC Form 15-12G. [Source](https://www.sec.gov/Archives/edgar/data/1854270/000119312526215046/d279858d1512g.htm) 7. 2026-05-01 Financings Reported a financing. SEC Form 424B5. [Source](https://www.sec.gov/Archives/edgar/data/1854270/000119312526201625/d118520d424b5.htm) 8. 2025-03-24 Financings Reported a financing. SEC Form 8-K (Items 1.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1854270/000114036125009939/ny20045827x2_8k.htm) 9. 2025-01-06 Financings Reported an unregistered sale of its securities. SEC Form 8-K (Items 2.03,3.02,8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1854270/000114036125000337/ef20040800_ex99-1.htm) 10. 2024-12-02 Financings Reported a financing. SEC Form 8-K (Items 1.01,2.03,3.02,3.03,5.02,5.03,8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1854270/000114036124048184/ef20039400_ex99-1.htm) ## Stock chart Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open NASDAQ:SNTI on TradingView](https://www.tradingview.com/symbols/NASDAQ-SNTI/). ## SEC filings and registration - **SEC name**: Senti Biosciences Holdings, Inc. - **CIK**: 1854270 - **Industry (SIC)**: Biological Products, (No Diagnostic Substances) (2836) - **US tickers**: SNTI (Nasdaq) - **State or country of incorporation**: DE - **Fiscal year ends**: December 31 - **Filer category**:
Emerging growth company - **Business address**: 2 CORPORATE DRIVE, FIRST FLOOR, SOUTH SAN FRANCISCO, CA, 94080 - **Phone**: (650) 239-2030 - **Shares outstanding**: 31,144,754 as of 2026-07-31 (10-Q filed 2026-08-14) - **Former names**: Senti Biosciences, Inc.; Senti Biosciences, Inc.\; Dynamics Special Purpose Corp. ### Recent filings (8-K and 6-K are the company's own announcements) - [8-K](https://www.sec.gov/Archives/edgar/data/1854270/000162828026065992/snti-20261015.htm) filed 2026-10-15 - [8-K](https://www.sec.gov/Archives/edgar/data/1854270/000162828026065685/snti-20261008.htm) filed 2026-10-13 - [8-K](https://www.sec.gov/Archives/edgar/data/1854270/000162828026063369/snti-20260923.htm) filed 2026-09-24 - [8-K](https://www.sec.gov/Archives/edgar/data/1854270/000162828026060600/snti-20260903.htm) filed 2026-09-04 - [8-K](https://www.sec.gov/Archives/edgar/data/1854270/000162828026060124/snti-20260827.htm) filed 2026-09-02 - [8-K](https://www.sec.gov/Archives/edgar/data/1854270/000162828026058258/snti-20260814.htm) filed 2026-08-20 - [10-Q](https://www.sec.gov/Archives/edgar/data/1854270/000162828026057110/snti-20260630.htm) filed 2026-08-14 - [8-K](https://www.sec.gov/Archives/edgar/data/1854270/000162828026048248/snti-20260714.htm) filed 2026-07-15 Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001854270), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices. ## Listing details Senti Biosciences Holdings, Inc. is a public biotech or pharmaceutical company listed on NASDAQ under the ticker SNTI, recorded under United States. The directory classifies it as Biotechnology. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them. - **Company**: Senti Biosciences Holdings, Inc. - **Ticker**: SNTI - **Listing**: NASDAQ - **Country or territory**: United States - **Business scope**: Biotechnology - **ISIN**: US8169441024 - **Last quote in directory**: 2026-10-21 - **Directory source**: [Listing page](https://www.tradingview.com/symbols/NASDAQ-SNTI/) Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/). Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/). Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update) --- Source page: https://aibio.space/companies/senti-biosciences/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Senti Biosciences Holdings (SNTI) news: offering", 2026-10-31, https://aibio.space/companies/senti-biosciences/